|View printer-friendly version|
ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium
ASLAN will present safety and efficacy data from an ongoing multicenter phase 1b/2 study of varlitinib plus gemcitabine and cisplatin in first line biliary tract cancer (BTC).
In a second poster, data from a pooled analysis of three phase 1 studies of varlitinib in combination with platinum-based regimens in BTC will be presented.
The full abstracts will be made available online via https://meetinglibrary.asco.org at
Abstract Title: A multicenter, phase 1b/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC).
Abstract Title: Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
Media and IR contacts
About varlitinib (ASLAN001)
Forward looking statements
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Source: ASLAN Pharmaceuticals Limited